The oncolytic virus dl922-947 triggers immunogenic cell death in mesothelioma and reduces Xenograft growth

Sarah Di Somma, Carmelina Antonella Iannuzzi, Carmela Passaro, Iris Maria Forte, Raffaella Iannone, Vincenzo Gigantino, Paola Indovina, Gerardo Botti, Antonio Giordano, Pietro Formisano, Giuseppe Portella, Anna Maria Malfitano, Francesca Pentimalli

Research output: Contribution to journalArticle

Abstract

Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer associated with asbestos exposure that urgently requires effective therapeutic strategies. Current treatments are unable to increase significantly patient survival, which is often limited to <1 year from diagnosis. Virotherapy, based on the use of oncolytic viruses that exert anti-cancer effects by direct cell lysis and through the induction of anti-tumor immune response, represents an alternative therapeutic option for rare tumors with limited life expectancy. In this study, we propose the use of the adenovirus dl922-947, engineered to allow selective replication in cancer cells, to counteract MPM. Methods: We performed a thorough preclinical assessment of dl922-947 effects in a set of MPM cell lines and xenografts. Cytotoxicity of dl922-947 alone and in combination assays was evaluated by sulforhodamine B assay. Cell cycle, calreticulin expression, and high mobility group box protein 1 (HMGB1) secretion were determined by flow cytometry, whereas ATP content was determined by a luminescence-based bioassay. The modulation of angiogenic factors in MPM-infected cells was evaluated through ELISA. Results: We found that dl922-947 infection exhibits cytotoxic effects in MPM cell lines, affecting cell viability, cell cycle progression, and regulating main hallmarks of immunogenic cell death inducing calreticulin surface exposure, HMGB1 and ATP release. Our results also suggest that dl922-947 may affect angiogenic signals by regulation of VEGF-A and IL-8 secretion. Furthermore, dl922-947 shows anti-tumor efficacy in murine xenograft models reducing tumor growth and enhancing survival. Finally, the combination with cisplatin potentiated the cytotoxic effect of dl922-947. Conclusions: Overall our data identify virotherapy, based on the use of dl922-947, as a new possible therapeutic strategy against MPM, which could be used alone, in combination with standard chemotherapy drugs, as shown here, or other approaches also aimed at enhancing the antitumoral immune response elicited by the virus.

Original languageEnglish
Article number564
JournalFrontiers in Oncology
Volume9
DOIs
Publication statusPublished - Jul 1 2019

Fingerprint

Oncolytic Viruses
Mesothelioma
Heterografts
Cell Death
Growth
Neoplasms
Calreticulin
HMGB1 Protein
lissamine rhodamine B
Cell Cycle
Adenosine Triphosphate
Cell Line
Survival
Angiogenesis Inducing Agents
Asbestos
Therapeutics
Life Expectancy
Luminescence
Interleukin-8
Adenoviridae

Keywords

  • Dl922-947
  • Immunogenic cell death
  • Mesothelioma
  • Oncolytic virus
  • Virotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The oncolytic virus dl922-947 triggers immunogenic cell death in mesothelioma and reduces Xenograft growth. / Di Somma, Sarah; Iannuzzi, Carmelina Antonella; Passaro, Carmela; Forte, Iris Maria; Iannone, Raffaella; Gigantino, Vincenzo; Indovina, Paola; Botti, Gerardo; Giordano, Antonio; Formisano, Pietro; Portella, Giuseppe; Malfitano, Anna Maria; Pentimalli, Francesca.

In: Frontiers in Oncology, Vol. 9, 564, 01.07.2019.

Research output: Contribution to journalArticle

Di Somma, Sarah ; Iannuzzi, Carmelina Antonella ; Passaro, Carmela ; Forte, Iris Maria ; Iannone, Raffaella ; Gigantino, Vincenzo ; Indovina, Paola ; Botti, Gerardo ; Giordano, Antonio ; Formisano, Pietro ; Portella, Giuseppe ; Malfitano, Anna Maria ; Pentimalli, Francesca. / The oncolytic virus dl922-947 triggers immunogenic cell death in mesothelioma and reduces Xenograft growth. In: Frontiers in Oncology. 2019 ; Vol. 9.
@article{4cc2ee2c7a4f4f2da70d58b930b56228,
title = "The oncolytic virus dl922-947 triggers immunogenic cell death in mesothelioma and reduces Xenograft growth",
abstract = "Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer associated with asbestos exposure that urgently requires effective therapeutic strategies. Current treatments are unable to increase significantly patient survival, which is often limited to <1 year from diagnosis. Virotherapy, based on the use of oncolytic viruses that exert anti-cancer effects by direct cell lysis and through the induction of anti-tumor immune response, represents an alternative therapeutic option for rare tumors with limited life expectancy. In this study, we propose the use of the adenovirus dl922-947, engineered to allow selective replication in cancer cells, to counteract MPM. Methods: We performed a thorough preclinical assessment of dl922-947 effects in a set of MPM cell lines and xenografts. Cytotoxicity of dl922-947 alone and in combination assays was evaluated by sulforhodamine B assay. Cell cycle, calreticulin expression, and high mobility group box protein 1 (HMGB1) secretion were determined by flow cytometry, whereas ATP content was determined by a luminescence-based bioassay. The modulation of angiogenic factors in MPM-infected cells was evaluated through ELISA. Results: We found that dl922-947 infection exhibits cytotoxic effects in MPM cell lines, affecting cell viability, cell cycle progression, and regulating main hallmarks of immunogenic cell death inducing calreticulin surface exposure, HMGB1 and ATP release. Our results also suggest that dl922-947 may affect angiogenic signals by regulation of VEGF-A and IL-8 secretion. Furthermore, dl922-947 shows anti-tumor efficacy in murine xenograft models reducing tumor growth and enhancing survival. Finally, the combination with cisplatin potentiated the cytotoxic effect of dl922-947. Conclusions: Overall our data identify virotherapy, based on the use of dl922-947, as a new possible therapeutic strategy against MPM, which could be used alone, in combination with standard chemotherapy drugs, as shown here, or other approaches also aimed at enhancing the antitumoral immune response elicited by the virus.",
keywords = "Dl922-947, Immunogenic cell death, Mesothelioma, Oncolytic virus, Virotherapy",
author = "{Di Somma}, Sarah and Iannuzzi, {Carmelina Antonella} and Carmela Passaro and Forte, {Iris Maria} and Raffaella Iannone and Vincenzo Gigantino and Paola Indovina and Gerardo Botti and Antonio Giordano and Pietro Formisano and Giuseppe Portella and Malfitano, {Anna Maria} and Francesca Pentimalli",
year = "2019",
month = "7",
day = "1",
doi = "10.3389/fonc.2019.00564",
language = "English",
volume = "9",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - The oncolytic virus dl922-947 triggers immunogenic cell death in mesothelioma and reduces Xenograft growth

AU - Di Somma, Sarah

AU - Iannuzzi, Carmelina Antonella

AU - Passaro, Carmela

AU - Forte, Iris Maria

AU - Iannone, Raffaella

AU - Gigantino, Vincenzo

AU - Indovina, Paola

AU - Botti, Gerardo

AU - Giordano, Antonio

AU - Formisano, Pietro

AU - Portella, Giuseppe

AU - Malfitano, Anna Maria

AU - Pentimalli, Francesca

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer associated with asbestos exposure that urgently requires effective therapeutic strategies. Current treatments are unable to increase significantly patient survival, which is often limited to <1 year from diagnosis. Virotherapy, based on the use of oncolytic viruses that exert anti-cancer effects by direct cell lysis and through the induction of anti-tumor immune response, represents an alternative therapeutic option for rare tumors with limited life expectancy. In this study, we propose the use of the adenovirus dl922-947, engineered to allow selective replication in cancer cells, to counteract MPM. Methods: We performed a thorough preclinical assessment of dl922-947 effects in a set of MPM cell lines and xenografts. Cytotoxicity of dl922-947 alone and in combination assays was evaluated by sulforhodamine B assay. Cell cycle, calreticulin expression, and high mobility group box protein 1 (HMGB1) secretion were determined by flow cytometry, whereas ATP content was determined by a luminescence-based bioassay. The modulation of angiogenic factors in MPM-infected cells was evaluated through ELISA. Results: We found that dl922-947 infection exhibits cytotoxic effects in MPM cell lines, affecting cell viability, cell cycle progression, and regulating main hallmarks of immunogenic cell death inducing calreticulin surface exposure, HMGB1 and ATP release. Our results also suggest that dl922-947 may affect angiogenic signals by regulation of VEGF-A and IL-8 secretion. Furthermore, dl922-947 shows anti-tumor efficacy in murine xenograft models reducing tumor growth and enhancing survival. Finally, the combination with cisplatin potentiated the cytotoxic effect of dl922-947. Conclusions: Overall our data identify virotherapy, based on the use of dl922-947, as a new possible therapeutic strategy against MPM, which could be used alone, in combination with standard chemotherapy drugs, as shown here, or other approaches also aimed at enhancing the antitumoral immune response elicited by the virus.

AB - Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer associated with asbestos exposure that urgently requires effective therapeutic strategies. Current treatments are unable to increase significantly patient survival, which is often limited to <1 year from diagnosis. Virotherapy, based on the use of oncolytic viruses that exert anti-cancer effects by direct cell lysis and through the induction of anti-tumor immune response, represents an alternative therapeutic option for rare tumors with limited life expectancy. In this study, we propose the use of the adenovirus dl922-947, engineered to allow selective replication in cancer cells, to counteract MPM. Methods: We performed a thorough preclinical assessment of dl922-947 effects in a set of MPM cell lines and xenografts. Cytotoxicity of dl922-947 alone and in combination assays was evaluated by sulforhodamine B assay. Cell cycle, calreticulin expression, and high mobility group box protein 1 (HMGB1) secretion were determined by flow cytometry, whereas ATP content was determined by a luminescence-based bioassay. The modulation of angiogenic factors in MPM-infected cells was evaluated through ELISA. Results: We found that dl922-947 infection exhibits cytotoxic effects in MPM cell lines, affecting cell viability, cell cycle progression, and regulating main hallmarks of immunogenic cell death inducing calreticulin surface exposure, HMGB1 and ATP release. Our results also suggest that dl922-947 may affect angiogenic signals by regulation of VEGF-A and IL-8 secretion. Furthermore, dl922-947 shows anti-tumor efficacy in murine xenograft models reducing tumor growth and enhancing survival. Finally, the combination with cisplatin potentiated the cytotoxic effect of dl922-947. Conclusions: Overall our data identify virotherapy, based on the use of dl922-947, as a new possible therapeutic strategy against MPM, which could be used alone, in combination with standard chemotherapy drugs, as shown here, or other approaches also aimed at enhancing the antitumoral immune response elicited by the virus.

KW - Dl922-947

KW - Immunogenic cell death

KW - Mesothelioma

KW - Oncolytic virus

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=85072071777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072071777&partnerID=8YFLogxK

U2 - 10.3389/fonc.2019.00564

DO - 10.3389/fonc.2019.00564

M3 - Article

VL - 9

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - 564

ER -